Certain aspects of the present disclosure relate generally to the detection of molecules, such as biomolecules, using functionalized particles, including microparticles. In one set of embodiments, a target molecule can be determined using magnetic particles and signaling particles that are able to bind to a portion of the target molecules. After allowing the magnetic and signaling particles to bind to the target molecule, e.g., to from a complex or an assembly, a magnetic field can be used to attract the magnetic particles, e.g., to a certain po sition. Determination of whether the signaling entity is present in the location, qualitatively or quantitatively, can then be used to determine the target molecule. Other embodiments are generally directed to systems for making or using such particles or assemblies, kits including these, or the like.

A microarray-based assay is provided, which is used for analyzing molecular interactions, including polynucleotides, polypeptides, antibodies, small molecule compounds, peptides and carbohydrates. Such method comprises coupling a target molecule to a particle and then binding to a probe molecule on microarray. In particular, multiplexed genetic analysis of nucleic acid fragments can be implemented. Specific genes, single nucleotide polymorphisms or gene mutations, such as deletions, insertions, and indels, can be identified. Coupled with microarray, the particles, themselves or further modified, facilitate the detection of results with non-expensive devices or even naked eyes. This technology enables the detection and interpretation of molecular interactions in an efficient and cost effective way.

The present invention relates to a porous substrate comprising at least one active agent entrapped within said pores of said substrate; wherein said pores are capped by at least one nucleic acid sequence; said agent is being released by a triggered reaction of said capping sequence with at least one analyte (biomarker) thereby allowing said capping to be cleaved from said pore. The invention further relates to methods of manufacturing said substrate, uses thereof for the controlled administration of active agents and diagnostic of conditions in a patient.

The present invention relates to a porous substrate comprising at least one active agent entrapped within said pores of said substrate; wherein said pores are capped by at least one nucleic acid sequence; said agent is being released by a triggered reaction of said capping sequence with at least one analyte (biomarker) thereby allowing said capping to be cleaved from said pore. The invention further relates to methods of manufacturing said substrate, uses thereof for the controlled administration of active agents and diagnostic of conditions in a patient.

The present disclosure relates to method and systems for amplifying nucleic acid molecule and quantify amplification thereof, with a polymerase chain reaction (PCR) or a loop-mediated isothermal amplification (LAMP), through bulk heating a biological enzymatic reaction mixture in solution containing nucleic acid templates, polymerase enzyme, and chemically modified nanoparticles. The method and system may comprise quantify amplification by irradiating the biological enzymatic reaction mixture during an annealing and/or elongation steps with an ultraviolet (UV) light source.

The present disclosure relates to method and systems for amplifying nucleic acid molecule and quantify amplification thereof, with a polymerase chain reaction (PCR) or a loop-mediated isothermal amplification (LAMP), through bulk heating a biological enzymatic reaction mixture in solution containing nucleic acid templates, polymerase enzyme, and chemically modified nanoparticles. The method and system may comprise quantify amplification by irradiating the biological enzymatic reaction mixture during an annealing and/or elongation steps with an ultraviolet (UV) light source.

Improved detection and tracking methods and systems are disclosed herein. The use of RFID labels that are operably connected upon complex formation in a binding assay is described as well as the use of RFID labels and supplemental identifiers to enhance component tracking in assay systems.

Improved detection and tracking methods and systems are disclosed herein. The use of RFID labels that are operably connected upon complex formation in a binding assay is described as well as the use of RFID labels and supplemental identifiers to enhance component tracking in assay systems.

Methods for screening a multiplicity of respiratory pathogens by isolating nucleic acids from a sample include isolating a nucleic acid from a sample and using solid phase amplification with forward primers SEQ ID NOs: 1 to 16 or 33 or 35 and corresponding reverse primers SEQ ID NOs: 17 to 32 or 34 or 36 along with probes to generate amplicons. The method further includes employing bead sets which are homogenous with respect to bead size and optionally with respect to the intensity of the label. Binding of a particular amplicon to a subset of beads determines the identity of the respiratory pathogen.

Methods for screening a multiplicity of respiratory pathogens by isolating nucleic acids from a sample include isolating a nucleic acid from a sample and using solid phase amplification with forward primers SEQ ID NOs: 1 to 16 or 33 or 35 and corresponding reverse primers SEQ ID NOs: 17 to 32 or 34 or 36 along with probes to generate amplicons. The method further includes employing bead sets which are homogenous with respect to bead size and optionally with respect to the intensity of the label. Binding of a particular amplicon to a subset of beads determines the identity of the respiratory pathogen.